Chemotherapy Related Topics 
STAT
OCTOBER 28, 2024
This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity.
STAT
OCTOBER 19, 2023
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JANUARY 17, 2024
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee for losing your hair. The company is currently developing an antibody that might reliably protect the head’s hair follicles from chemotherapy damage — if it works. But, to her, it wasn’t much of an option.
STAT
JUNE 6, 2023
After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy supplier, the Food and Drug Administration will not allow the company to resume distribution in the U.S. beyond some cancer medicines that are in short supply.
STAT
APRIL 14, 2025
An increasing challenge in the treatment of oral cancer is that tumors become resistant to chemotherapy. The medical promise of CRISPR gene editing can be seen most easily in current research on oral cancer, which affects more than 50,000 Americans every year.
STAT
MARCH 5, 2025
It responds poorly to chemotherapy and is usually driven by a mutation that can’t be drugged with traditional approaches. The tumor, known as diffuse midline glioma, or DMG (and sometimes as DIPG depending on where it’s found), has flummoxed researchers for decades. Median survival is generally cited as less than a year.
STAT
JANUARY 22, 2024
Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed. Continue to STAT+ to read the full story…
Expert insights. Personalized for you.
350 
Let's personalize your content